Immunic exhibits extremely high price volatility, a standard trait among clinical-stage biopharmaceutical equities listed on public exchanges. Share valuations can experience sharp percentage swings within single trading sessions based on clinical trial updates, regulatory disclosures, secondary equity offerings, or broader market sentiment shifts. Investors trading or holding the stock must be prepared for substantial price fluctuations, wide bid-ask spreads, and rapid momentum changes driven by corporate financing milestones and developmental pipeline readouts.